- Home
- AIFU vs INDP Comparison
AIFU vs INDP Comparison
Compare AIFU & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- INDP
- Stock Information
- Founded
- AIFU 1998
- INDP 2000
- Country
- AIFU China
- INDP United States
- Employees
- AIFU N/A
- INDP N/A
- Industry
- AIFU
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- INDP Health Care
- Exchange
- AIFU NYSE
- INDP Nasdaq
- Market Cap
- AIFU 7.2M
- INDP 7.4M
- IPO Year
- AIFU 2007
- INDP N/A
- Fundamental
- Price
- AIFU $0.12
- INDP $0.47
- Analyst Decision
- AIFU
- INDP Strong Buy
- Analyst Count
- AIFU 0
- INDP 2
- Target Price
- AIFU N/A
- INDP $8.50
- AVG Volume (30 Days)
- AIFU 645.1K
- INDP 71.0K
- Earning Date
- AIFU 05-06-2025
- INDP 05-07-2025
- Dividend Yield
- AIFU N/A
- INDP N/A
- EPS Growth
- AIFU N/A
- INDP N/A
- EPS
- AIFU 0.38
- INDP N/A
- Revenue
- AIFU $324,923,970.00
- INDP N/A
- Revenue This Year
- AIFU N/A
- INDP N/A
- Revenue Next Year
- AIFU $11.81
- INDP N/A
- P/E Ratio
- AIFU $0.32
- INDP N/A
- Revenue Growth
- AIFU N/A
- INDP N/A
- 52 Week Low
- AIFU $0.12
- INDP $0.43
- 52 Week High
- AIFU $3.84
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- INDP 36.28
- Support Level
- AIFU N/A
- INDP $0.45
- Resistance Level
- AIFU N/A
- INDP $0.53
- Average True Range (ATR)
- AIFU 0.00
- INDP 0.04
- MACD
- AIFU 0.00
- INDP 0.01
- Stochastic Oscillator
- AIFU 0.00
- INDP 41.41
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.